Lars Erik Bryld

Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

Alexander Egeberg, Mathias Bo Ottosen, Robert Gniadecki et al. · British Journal of Dermatology · 2017 · 282 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

Robert Gniadecki, B K Bang, Lars Erik Bryld et al. · British Journal of Dermatology · 2014 · 278 citations

Pharmacy, Dermatology, Pharmacotherapy +16

Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort

Ole Ahlehoff, Lone Skov, Gunnar Gislason et al. · Journal of the European Academy of Dermatology and Venereology · 2014 · 190 citations

Medicine, Pharmacology, Pharmacotherapy +14

Risk factors influencing the development of hand eczema in a population-based twin sample

Lars Erik Bryld, Charlotte Hindsberger, Kirsten Ohm Kyvik et al. · British Journal of Dermatology · 2003 · 179 citations

Life Sciences, Dermatology, Genetics +17

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Thein et al. · Seminars in Arthritis and Rheumatism · 2022 · 87 citations

Medicine, Immunology, Pharmacology +17